Page last updated: 2024-11-13
hmpl-013
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
HMPL-013: a VEGF receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 44480399 |
CHEMBL ID | 4303214 |
SCHEMBL ID | 947183 |
MeSH ID | M000598336 |
Synonyms (45)
Synonym |
---|
S5667 |
6-((6,7-dimethoxyquinazolin-4-yl)oxy)-n,2-dimethylbenzofuran-3-carboxamide |
hmpl 013 |
BALLNEJQLSTPIO-UHFFFAOYSA-N |
6-(6,7-dimethoxyquinazolin-4-yloxy)-n,2-dimethylbenzofuran-3-carboxamide |
SCHEMBL947183 |
hmpl013 |
fruquintinib [inn] |
elunate |
gtpl9428 |
fruquintinib [usan:who-dd] |
unii-49dxg3m5zw |
fruquintinib [who-dd] |
3-benzofurancarboxamide, 6-((6,7-dimethoxy-4-quinazolinyl)oxy)-n,2-dimethyl- |
fruquintinib , |
who 10348 |
49dxg3m5zw , |
1194506-26-7 |
6-(6,7-dimethoxyquinazolin-4-yl)oxy-n,2-dimethyl-1-benzofuran-3-carboxamide |
hmpl-013 |
fruquintinib [usan] |
HY-19912 |
CS-5558 |
AKOS026750586 |
6-[(6,7-dimethoxyquinazolin-4-yl)oxy]-n,2-dimethyl-1-benzofuran-3-carboxamide |
AS-73141 |
fruquintinib (hmpl-013) |
DB11679 |
BCP15692 |
hmpl-013;hmpl013;hmpl 013 |
fruquintinib; hmpl-013 |
EX-A2262 |
6-[(6,7-dimethoxy-4-quinazolinyl)oxy]-n,2-dimethyl-3-benzofurancarboxamide |
SB17123 |
CCG-268573 |
CHEMBL4303214 |
NCGC00481603-01 |
Q27259271 |
nsc-829498 |
nsc829498 |
C71641 |
B2693-470819 |
A898991 |
nsc801000 |
nsc-801000 |
Research Excerpts
Toxicity
Pharmacokinetics
Bioavailability
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" It would require high potency (low effective drug concentrations) and sufficient drug exposures at tolerated doses so that the drug concentration can be maintained above effective drug concentration for target inhibition within the dosing period." | ( Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cai, H; Cui, Y; Gu, Y; Guo, M; Hong, M; Liang, J; Long, J; Ni, L; Qing, W; Ren, Y; Sai, Y; Su, W; Sun, J; Sun, Q; Yang, H; Yang, Z; Yin, F; Zhang, M; Zhang, W; Zhang, Z; Zhou, F; Zhou, J, 2014) | 0.4 |
" Steady-state was achieved after 14 days of QD dosing with systemic exposure four-fold higher than that after a single dose." | ( Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States. Chien, C; Gonzalez, M; Kania, M; Schelman, W; Ukrainskyj, S; Wang-Gillam, A; Yang, Z; Yeckes-Rodin, H, 2023) | 0.91 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (6)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1345548 | Human fms related tyrosine kinase 1 (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family) | 2014 | Cancer biology & therapy, , Volume: 15, Issue:12 | Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. |
AID1345520 | Human fms related tyrosine kinase 4 (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family) | 2014 | Cancer biology & therapy, , Volume: 15, Issue:12 | Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. |
AID1345506 | Human kinase insert domain receptor (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family) | 2014 | Cancer biology & therapy, , Volume: 15, Issue:12 | Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (43)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 17 (39.53) | 24.3611 |
2020's | 26 (60.47) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 18.26
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.26) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 13 (29.55%) | 5.53% |
Reviews | 8 (18.18%) | 6.00% |
Case Studies | 2 (4.55%) | 4.05% |
Observational | 2 (4.55%) | 0.25% |
Other | 19 (43.18%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |